Survivin-responsive Conditionally Replicating Adenovirus for Patients with Advanced Sarcoma Demonstrated Potent and Longterm Efficacy and High Safety in Phase 1 Clinical Trial.
Survivin-responsive Conditionally Replicating Adenovirus for Patients with Advanced Sarcoma Demonstrated Potent and Longterm Efficacy and High Safety in Phase 1 Clinical Trial.
复制标题
针对晚期肉瘤患者的生存素反应性条件复制腺病毒在 1 期临床试验中显示出有效的长期疗效和高安全性。
DOI：
--
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Ken-ichiro Kosai.
中科院分区：
文献类型：
--
作者：
Satoshi Nagano;Toshitaka Futagawa;Eriko Sumi;Nobuhiro Ijichi;Munekazu Yamakuchi;Masanori Nakajo;Teruto Hashiguchi;Yasuo Takeda;Takashi Yoshiura;Akira Shimizu;Muneo Takatani;Setsuro Komiya;Ken-ichiro Kosai.
